Pharmaceuticals North America (NAFTA) Industry Guide_2016

Date: October 18, 2016
Pages: 79
Price:
US$ 795.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PA2263FE3C5EN
Leaflet:

Download PDF Leaflet

Pharmaceuticals North America (NAFTA) Industry Guide_2016
SUMMARY

The NAFTA Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY FINDINGS
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players' NAFTA operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA pharmaceuticals market with five year forecasts
  • Compares data from the US, Canada and Mexico, alongside individual chapters on each country
SYNOPSIS

Essential resource for top-line data and analysis covering the NAFTA pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

REASONS TO BUY
  • What was the size of the NAFTA pharmaceuticals market by value in 2015?
  • What will be the size of the NAFTA pharmaceuticals market in 2020?
  • What factors are affecting the strength of competition in the NAFTA pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the NAFTA pharmaceuticals market?
KEY HIGHLIGHTS
  • The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The pharmaceuticals industry within the NAFTA countries had a total market value of $411.4 billion in 2015.The Canada was the fastest growing country, with a CAGR of 6.2% over the 2011-15 period.
  • Within the pharmaceuticals industry, the US is the leading country among the NAFTA bloc, with market revenues of $383.8 billion in 2015. This was followed by Canada and Mexico, with a value of $19.2 and $8.4 billion, respectively.
  • The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $422.9 billion in 2020, followed by Canada and Mexico with expected values of $31.7 and $9.3 billion, respectively.
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA Pharmaceuticals
Industry Outlook
The US is expected to lead the pharmaceuticals industry in the NAFTA bloc, with a value of $. billion in , followed by Canada and Mexico with expected values of $. and $. billion, respectively.
Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

LIST OF TABLES

Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2011-20
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2011-15
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2015-20
Table 4: Canada pharmaceuticals market value: $ billion, 2011-15
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2015
Table 6: Canada pharmaceuticals market share: % share, by value, 2015
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2015-20
Table 8: Canada size of population (million), 2011-15
Table 9: Canada gdp (constant 2005 prices, $ billion), 2011-15
Table 10: Canada gdp (current prices, $ billion), 2011-15
Table 11: Canada inflation, 2011-15
Table 12: Canada consumer price index (absolute), 2011-15
Table 13: Canada exchange rate, 2011-15
Table 14: Mexico pharmaceuticals market value: $ billion, 2011-15
Table 15: Mexico pharmaceuticals market geography segmentation: $ billion, 2015
Table 16: Mexico pharmaceuticals market share: % share, by value, 2015
Table 17: Mexico pharmaceuticals market value forecast: $ billion, 2015-20
Table 18: Mexico size of population (million), 2011-15
Table 19: Mexico gdp (constant 2005 prices, $ billion), 2011-15
Table 20: Mexico gdp (current prices, $ billion), 2011-15
Table 21: Mexico inflation, 2011-15
Table 22: Mexico consumer price index (absolute), 2011-15
Table 23: Mexico exchange rate, 2011-15
Table 24: United States pharmaceuticals market value: $ billion, 2011-15
Table 25: United States pharmaceuticals market geography segmentation: $ billion, 2015
Table 26: United States pharmaceuticals market share: % share, by value, 2015
Table 27: United States pharmaceuticals market value forecast: $ billion, 2015-20
Table 28: United States size of population (million), 2011-15
Table 29: United States gdp (constant 2005 prices, $ billion), 2011-15
Table 30: United States gdp (current prices, $ billion), 2011-15
Table 31: United States inflation, 2011-15
Table 32: United States consumer price index (absolute), 2011-15
Table 33: United States exchange rate, 2011-15
Table 34: Apotex, Inc.: key facts
Table 35: Johnson and Johnson: key facts
Table 36: Johnson and Johnson: key financials ($)
Table 37: Johnson and Johnson: key financial ratios
Table 38: Merck and Co., Inc.: key facts
Table 39: Merck and Co., Inc.: key financials ($)
Table 40: Merck and Co., Inc.: key financial ratios
Table 41: Pfizer Inc.: key facts
Table 42: Pfizer Inc.: key financials ($)
Table 43: Pfizer Inc.: key financial ratios
Table 44: Bayer AG: key facts
Table 45: Bayer AG: key financials ($)
Table 46: Bayer AG: key financials (€)
Table 47: Bayer AG: key financial ratios
Table 48: Novartis AG: key facts
Table 49: Novartis AG: key financials ($)
Table 50: Novartis AG: key financial ratios
Table 51: GlaxoSmithKline Plc: key facts
Table 52: GlaxoSmithKline Plc: key financials ($)
Table 53: GlaxoSmithKline Plc: key financials (£)
Table 54: GlaxoSmithKline Plc: key financial ratios

LIST OF FIGURES

Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2011-20
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2011-15
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2015-20
Figure 4: Canada pharmaceuticals market value: $ billion, 2011-15
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 6: Canada pharmaceuticals market share: % share, by value, 2015
Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2015-20
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2015
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2015
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2015
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2015
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2015
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2015
Figure 14: Mexico pharmaceuticals market value: $ billion, 2011-15
Figure 15: Mexico pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 16: Mexico pharmaceuticals market share: % share, by value, 2015
Figure 17: Mexico pharmaceuticals market value forecast: $ billion, 2015-20
Figure 18: Forces driving competition in the pharmaceuticals market in Mexico, 2015
Figure 19: Drivers of buyer power in the pharmaceuticals market in Mexico, 2015
Figure 20: Drivers of supplier power in the pharmaceuticals market in Mexico, 2015
Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2015
Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2015
Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2015
Figure 24: United States pharmaceuticals market value: $ billion, 2011-15
Figure 25: United States pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 26: United States pharmaceuticals market share: % share, by value, 2015
Figure 27: United States pharmaceuticals market value forecast: $ billion, 2015-20
Figure 28: Forces driving competition in the pharmaceuticals market in the United States, 2015
Figure 29: Drivers of buyer power in the pharmaceuticals market in the United States, 2015
Figure 30: Drivers of supplier power in the pharmaceuticals market in the United States, 2015
Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2015
Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2015
Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2015
Figure 34: Johnson and Johnson: revenues and profitability
Figure 35: Johnson and Johnson: assets and liabilities
Figure 36: Merck and Co., Inc.: revenues and profitability
Figure 37: Merck and Co., Inc.: assets and liabilities
Figure 38: Pfizer Inc.: revenues and profitability
Figure 39: Pfizer Inc.: assets and liabilities
Figure 40: Bayer AG: revenues and profitability
Figure 41: Bayer AG: assets and liabilities
Figure 42: Novartis AG: revenues and profitability
Figure 43: Novartis AG: assets and liabilities
Figure 44: GlaxoSmithKline Plc: revenues and profitability
Figure 45: GlaxoSmithKline Plc: assets and liabilities
Skip to top


Ask Your Question

Pharmaceuticals North America (NAFTA) Industry Guide_2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: